The outpatient management of febrile neutropenia in cancer patients

Alison G. Freifeld, Philip A. Pizzo

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Treatment of fever and neutropenia in cancer patients has been recognized for 30 years as a medical emergency, requiring prompt in-hospital evaluation and institution of broad-spectrum intravenous (IV) antibiotics. This action was deemed necessary due to the high frequency of life-threatening infections in febrile neutropenic patients, with no way to distinguish patients who are infected from those who are not. In recent years, it has become clear that not all neutropenic cancer patients are at the same level of risk for developing severe infections or life-threatening complications during neutropenia. Those who are at low risk may be candidates for treatment outside the hospital setting, either with IV regimens or potent oral antibiotics. The identification of low-risk febrile neutropenic patients and the specific outpatient approaches that have been tested to date are discussed. Outpatient management of fever during neutropenia could obviously be much less costly than standard inpatient care and could improve quality of life for low-risk patients undergoing cancer therapy.

Original languageEnglish (US)
Pages (from-to)599-612
Number of pages14
JournalONCOLOGY
Volume10
Issue number4
StatePublished - Apr 1 1996

Fingerprint

Febrile Neutropenia
Outpatients
Fever
Neutropenia
Neoplasms
Naphazoline
Anti-Bacterial Agents
Infection
Inpatients
Emergencies
Therapeutics
Quality of Life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The outpatient management of febrile neutropenia in cancer patients. / Freifeld, Alison G.; Pizzo, Philip A.

In: ONCOLOGY, Vol. 10, No. 4, 01.04.1996, p. 599-612.

Research output: Contribution to journalArticle

Freifeld, Alison G. ; Pizzo, Philip A. / The outpatient management of febrile neutropenia in cancer patients. In: ONCOLOGY. 1996 ; Vol. 10, No. 4. pp. 599-612.
@article{cf9b47f97dfb474f8c4b18e53d33e63d,
title = "The outpatient management of febrile neutropenia in cancer patients",
abstract = "Treatment of fever and neutropenia in cancer patients has been recognized for 30 years as a medical emergency, requiring prompt in-hospital evaluation and institution of broad-spectrum intravenous (IV) antibiotics. This action was deemed necessary due to the high frequency of life-threatening infections in febrile neutropenic patients, with no way to distinguish patients who are infected from those who are not. In recent years, it has become clear that not all neutropenic cancer patients are at the same level of risk for developing severe infections or life-threatening complications during neutropenia. Those who are at low risk may be candidates for treatment outside the hospital setting, either with IV regimens or potent oral antibiotics. The identification of low-risk febrile neutropenic patients and the specific outpatient approaches that have been tested to date are discussed. Outpatient management of fever during neutropenia could obviously be much less costly than standard inpatient care and could improve quality of life for low-risk patients undergoing cancer therapy.",
author = "Freifeld, {Alison G.} and Pizzo, {Philip A.}",
year = "1996",
month = "4",
day = "1",
language = "English (US)",
volume = "10",
pages = "599--612",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - The outpatient management of febrile neutropenia in cancer patients

AU - Freifeld, Alison G.

AU - Pizzo, Philip A.

PY - 1996/4/1

Y1 - 1996/4/1

N2 - Treatment of fever and neutropenia in cancer patients has been recognized for 30 years as a medical emergency, requiring prompt in-hospital evaluation and institution of broad-spectrum intravenous (IV) antibiotics. This action was deemed necessary due to the high frequency of life-threatening infections in febrile neutropenic patients, with no way to distinguish patients who are infected from those who are not. In recent years, it has become clear that not all neutropenic cancer patients are at the same level of risk for developing severe infections or life-threatening complications during neutropenia. Those who are at low risk may be candidates for treatment outside the hospital setting, either with IV regimens or potent oral antibiotics. The identification of low-risk febrile neutropenic patients and the specific outpatient approaches that have been tested to date are discussed. Outpatient management of fever during neutropenia could obviously be much less costly than standard inpatient care and could improve quality of life for low-risk patients undergoing cancer therapy.

AB - Treatment of fever and neutropenia in cancer patients has been recognized for 30 years as a medical emergency, requiring prompt in-hospital evaluation and institution of broad-spectrum intravenous (IV) antibiotics. This action was deemed necessary due to the high frequency of life-threatening infections in febrile neutropenic patients, with no way to distinguish patients who are infected from those who are not. In recent years, it has become clear that not all neutropenic cancer patients are at the same level of risk for developing severe infections or life-threatening complications during neutropenia. Those who are at low risk may be candidates for treatment outside the hospital setting, either with IV regimens or potent oral antibiotics. The identification of low-risk febrile neutropenic patients and the specific outpatient approaches that have been tested to date are discussed. Outpatient management of fever during neutropenia could obviously be much less costly than standard inpatient care and could improve quality of life for low-risk patients undergoing cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029948620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029948620&partnerID=8YFLogxK

M3 - Article

C2 - 8723296

AN - SCOPUS:0029948620

VL - 10

SP - 599

EP - 612

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 4

ER -